|
|
Article: Favorable Soriatane Cost-Effectiveness Analysis is Published in Leading Managed Care Journal.
- Article from:
- Business Wire
- Article date:
- May 11, 2005
CopyrightCOPYRIGHT 2005 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
PALO ALTO, Calif. -- Connetics Corporation (Nasdaq:CNCT), a specialty pharmaceutical company that develops and commercializes dermatology products, announced today that a study comparing the cost-effectiveness of systemic treatments for psoriasis was published in the May issue of Drug Benefit Trends after being presented in a poster at the 17th Academy of Managed Care Pharmacy annual meeting held April 20th to 23rd in Denver. The publication demonstrates that Soriatane(R) (acitretin) is more cost-effective than biologics. Additionally, in combination with UV light therapy, Soriatane demonstrated a highly favorable cost-to-benefit profile in comparison to the other ...